TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer

JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the Company has appointed Dr. John N. Bonfiglio, a member of its Board of Directors, as the Company’s President…

Details

TapImmune Doses First Patient in its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

Cancer vaccine TPIV 200 to be evaluated in four Phase 2 trials in 2016 JACKSONVILLE, FL, June 21, 2016 / TapImmune,Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced reaching a major milestone of dosing its…

Details

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute

JACKSONVILLE, Florida, April 21, 2016 /PRNewswire/ – Study to commence Q2 2016 at Sloan Kettering Institute Cancer vaccine and checkpoint inhibitor combination to be evaluated in platinum-resistant ovarian cancer patients TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic…

Details

TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine

Doses for use at Mayo Clinic and other clinical sites Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has…

Details

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

TapImmune-Corporate-Presentation-2016 JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company’s Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at…

Details

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice…

Details